Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.52 |
| ▸ | ACACB | O00763 | 8/20 | 0.47 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20858757 | 0.81 | GRIN2B (0.57) | GRIN2BACACBGRM4HCRTR1HCRTR2 | |
| SCHEMBL4483176 | 0.80 | GRIN2B (0.56) | GRIN2BACACBGRM4HCRTR1HCRTR2 | |
| SCHEMBL26089575 | 0.79 | EIF2AK4 (0.41) | GRIN2BACACBEIF2AK4 | |
| SCHEMBL23744097 | 0.79 | EIF2AK4 (0.41) | GRIN2BACACBEIF2AK4 | |
| SCHEMBL30345475 | 0.79 | EIF2AK4 (0.41) | GRIN2BACACBEIF2AK4 | |
| SCHEMBL20283153 | 0.79 | GRIN2B (0.52) | GRIN2BACACBGRM4HCRTR1HCRTR2 | |
| SCHEMBL23744051 | 0.77 | CHRNB4 (0.42) | EIF2AK4 | |
| SCHEMBL25154530 | 0.77 | GRIN2B (0.60) | GRIN2BACACBGRM4HCRTR1HCRTR2 | |
| SCHEMBL7395229 | 0.77 | GRIN2B (0.53) | GRIN2BACACBGRM4HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL9005361 | 0.76 | GRIN2B (0.52) | GRIN2BACACBGRM4HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513088-B1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2015-07-01 | — | — | EP | disclosed |
| EP-2513108-B1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALCANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2015-04-01 | — | — | EP | disclosed |
| US-8957211-B2 | (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors | SANOFI (FR) | 2015-02-17 | — | — | US | disclosed |
| US-20140038946-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS | SANOFI (FR) | 2014-02-06 | — | — | US | disclosed |
| US-20130303520-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS | SANOFI (FR) | 2013-11-14 | — | — | US | disclosed |
| US-8580790-B2 | (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| EP-2513088-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI (FR) | 2012-10-24 | — | — | EP | disclosed |
| EP-2513108-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALCANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI (FR) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245149-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245150-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011080445-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080444-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALCANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038946-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS | NTRK2, NTRK3, NGF | GRIN2B 629/4885ACACB 787/4885EIF2AK4 426/4885 |
| US-20120245150-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS | NTRK2, NTRK1, NTRK3 | GRIN2B 454/4885ACACB 538/4885EIF2AK4 708/4885 |
| US-20120245149-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS | NTRK2, NTRK3, NGF | GRIN2B 637/4885ACACB 812/4885EIF2AK4 358/4885 |
| US-20130303520-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS | NTRK2, NTRK1, NTRK3 | GRIN2B 454/4885ACACB 538/4885EIF2AK4 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.